Quality standards for preclinical research in cardio-oncology

The authors aim to establish quality standards for preclinical research in cardio-oncology, specifically addressing cancer therapy-related cardiovascular toxicity (CTR-CVT). They highlight the need for a systematic approach to experimental model selection and reporting methods, advocating for first-tier and second-tier standards to enhance the reliability and reproducibility of studies. By promoting these standards, the authors hope to advance research in this field, improve funding allocation, and support the development of new cancer therapies.